Kenneth Schaecher
Internal Medicine · West Valley City, UTNPI 1245262492
Payments from drug & device makers
Across 462 payments — averaging $721.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$153K
- Boehringer Ingelheim$16K
- Eli Lilly$16K
- Pacira Pharmaceuticals Incorporated$10K
- Astrazeneca UK Limited$9K
- Lilly USA, LLC$9K
- plus $121K from 48 others
What the payments were for
- Consulting fees$241,68373%
- Speaking & faculty fees$31,1989%
- Travel & lodging$46,92214%
- Food & beverage$12,8344%
- Education$790%
- Gifts$5810%
- Entertainment$130%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$75,439
- Non-Covered$18,749
- EXPAREL$9,446
- Zilretta$9,300
- KISUNLA$8,800
- BB-2121$7,677
- Nubeqa$7,614
- VYVGART$7,318
- VYVGART HYTRULO$7,318
- ADSTILADRIN$7,197
- OFEV$7,183
- CAPLYTA$6,083
- EPKINLY$5,426
- TALTZ$4,400
- REXULTI$3,500
- IMFINZI$3,157
- TALZENNA$3,140
- NovaSeq 6000Dx Sequencer Instrument$2,364
- Vascepa$1,750
- Lucemyra/Lofexidine$1,750
How this compares
$333,329 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $9,624 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 19 | $506 |
| Olmesartan Medoxomil | 24 | $494 |
| Atorvastatin Calcium | 34 | $311 |
| Omeprazole | 14 | $279 |
| Metoprolol Succinate | 17 | $211 |
| Meloxicam | 33 | $207 |
| Tramadol Hcl | 22 | $175 |
| Levothyroxine Sodium | 15 | $153 |
| Potassium Chloride | 13 | $136 |
| Finasteride | 11 | $133 |
| Amlodipine Besylate | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy | $16,290 | $9,62413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in West Valley City
- Cuper Martinez SantibanezWest Valley City$1M
- Roy GandolfiWest Valley City$12K
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.